|Dr. Maria Fardis||CEO, Pres & Director||850k||N/A||1968|
|Mr. Timothy E. Morris||CFO, Principal Accounting Officer & Corp. Sec.||525.97k||N/A||1962|
|Dr. Frederick G. Vogt Ph.D., Esq.||Gen. Counsel||457.75k||N/A||1974|
|Mr. Howard B. Johnson||Sr. VP of Corp. Devel., Alliance Management & Program Management||N/A||N/A||1960|
|Dr. Elma S. Hawkins Ph.D., MBA||Advisor to the Board||N/A||N/A||1957|
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Iovance Biotherapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2019 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 9.